The EC has requested information from to pharmaceutical companies, including copies of patent settlement agreements affecting the EU between originator and generic pharmaceutical companies from July 1, 2008, to December 31, 2009. The Commission is focused on situations in which the pioneer company a potential generic competitor in return for delaying the market entry of a generic drug.